Anti-Human CD68 FITC 25 tests
- Known as:
- Antibody toHuman CD68 fluorecein 25 tests
- Catalog number:
- 11-0689-71
- Category:
- -
- Supplier:
- eBioscience
- Gene target:
- Anti-Human CD68 FITC 25 tests
Related genes to: Anti-Human CD68 FITC 25 tests
- Gene:
- CD68 NIH gene
- Name:
- CD68 molecule
- Previous symbol:
- -
- Synonyms:
- SCARD1, macrosialin, GP110, DKFZp686M18236, LAMP4
- Chromosome:
- 17p13.1
- Locus Type:
- gene with protein product
- Date approved:
- 1993-06-11
- Date modifiied:
- 2016-10-05
Related products to: Anti-Human CD68 FITC 25 tests
Related articles to: Anti-Human CD68 FITC 25 tests
- Chronic inflammation and inflammation-associated local microenvironmental imbalance are critical barriers to effective wound healing, while conventional dressings remain functionally limited. Here, we developed a drug-loaded passive cooling nanocomposite hydrogel that can simultaneously regulate the physical temperature and biochemical wound microenvironment. The hydrogel is constructed from a poly(vinyl alcohol)-sorbitol network incorporating sulfated cellulose nanocrystals, silica nanoparticles, and salidroside, a potent anti-inflammatory phytochemical, achieving both exceptional passive cooling with a temperature drop of 6.2°C compared to non-covered control under sunlight and the sustained release of salidroside. In vitro, the hydrogel exhibits time-dependent antibacterial efficacy over 97% bacterial inhibition and effectively suppresses inflammation. In a murine full-thickness wound model, the hydrogel promoted local cooling and accelerated wound closure, achieving near-complete healing by day 11, earlier than the phosphate-buffered saline control. Histological analyses confirm attenuated inflammation and enhanced tissue remodeling, as evidenced by suppressed TNF-α expression and CD68 macrophage infiltration, increased α-SMA myofibroblasts, and organized collagen deposition. This work introduces a cooling-and-curing strategy, where material enables physical cooling and localized drug delivery to operate synergistically to disrupt the inflammatory cycle, offering a transformative platform for intelligent wound management. - Source: PubMed
Publication date: 2026/09/15
Ding LiHuang JingFeng KaiWu HuangzhipengChen ShuZhang ZipengWang HaixinWang JinChen ShengShen QingchenZhong Yuyue - The tumor immune microenvironment (TME) critically influences cancer progression and therapeutic response. However, the pan-cancer expression landscape, prognostic relevance, and spatial distribution of ZDHHC12 remain incompletely characterized. This study investigated the prognostic value of ZDHHC12 and its associations with immune microenvironmental features and drug sensitivity. - Source: PubMed
Publication date: 2026/09/03
Zhang ChaoTeng DaWang YuHou ShiqiangZhang WenjunLin Ning - This image report aims to illustrate the diagnostic value of integrating various diagnostic modalities to distinguish angiomatoid fibrous histiocytoma (AFH) from malignant soft tissue tumors. A 33-year-old man presented with a painful palpable mass in the medial left thigh. Magnetic resonance imaging revealed a 27 × 23 × 20 mm intramuscular lesion in the vastus medialis with a mixed T1 signal, predominantly high T2/STIR signal, internal hyperintense foci, a capsule-like rim, septations, heterogeneous enhancement, and marked peritumoral edema extending beyond the apparent tumor margins. Because these findings raised concern for a malignant soft tissue tumor, wide excision was performed after biopsy suggestive of low-grade sarcoma. Histologically, the tumor comprised spindle to epithelioid cells arranged in fascicular and storiform patterns surrounded by a lymphoid cuff. Immunohistochemistry showed positivity for CD68, CD99, and EMA, partial desmin and S-100 expression, and a Ki-67 index of 15%. Differential diagnosis included AFH and a malignant peripheral nerve sheath tumor. FISH demonstrated EWSR1 rearrangement, while PCR testing for EWSR1-CREB1 and EWSR1-ATF1 was negative. Although the specific fusion partner could not be identified, an EWSR1 rearrangement, together with the histologic and immunohistochemical findings, was considered supportive but not definitive for AFH. AFH, a rare intermediate tumor with nonspecific imaging features and variable pathology, makes diagnosis challenging. This case emphasizes the need to consider AFH in the diagnosis of intramuscular tumors with disproportionate peritumoral edema and highlights the role of molecular analysis in confirming the diagnosis. - Source: PubMed
Publication date: 2026/08/30
Kawasaki TomonoriIchikawa JiroKanno SatoshiTorigoe TomoakiWatanabe TakuyaHirasaki MasatakaWako MasanoriHagino TetsuhiroTatsuno RikitoOnohara KojiroEnomoto AtsushiNojima Takayuki - Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma that is histologically and clinically heterogeneous. Skeletonization is a computer vision technique used in image description, segmentation, and pattern recognition. - Source: PubMed
Publication date: 2026/09/01
Carreras JoaquimKikuti Yara YukieNagase ShunsukeRoncador GiovannaIkoma HarukaIto AtsushiOrita MakotoTomita SakuraTanigaki YukiUeno AkihisaKondo YusukeNakamura NaoyaMasugi Yohei - Eosinophilic chronic rhinosinusitis with nasal polyps (eCRSwNP) is characterized by type 2 inflammation, including M2 macrophage infiltration. Baicalein is a flavonoid with anti-inflammatory properties. This study aimed to investigate the therapeutic effect of baicalein in a papain-induced eosinophilic rhinosinusitis model and to determine whether it acts through arachidonate 15-lipoxygenase (ALOX15)-dependent M2 macrophage function. Clinical nasal samples from controls, non-eosinophilic CRSwNP (neCRSwNP), and eCRSwNP were analyzed for ALOX15 expression and localization. THP-1 cells were differentiated and polarized toward M2 macrophages, and the effects of baicalein on ALOX15 expression, lipid peroxidation, cytokine secretion, and transcriptomic profile were examined. The ALOX15 inhibitor PD146176 was used for target validation. A murine eosinophilic rhinosinusitis model was established by intranasal papain instillation, followed by baicalein treatment. Mucosal inflammation, IgE levels, proteoglycan 2 (PRG2)/ALOX15 expression, and immune cell infiltration were evaluated. ALOX15 was upregulated in eCRSwNP tissues and localized to CD68CD206 M2 macrophages. In vitro, M2 polarization increased ALOX15 expression and lipid peroxidation. Baicalein suppressed ALOX15 expression, lipid peroxidation, and the secretion of CCL22, CCL2, CXCL12, FGF-2, and IL-15. PD146176 produced similar effects, and baicalein showed no additional effect after ALOX15 blockade. RNA sequencing revealed transcriptional remodeling in M2 macrophages after baicalein treatment. In vivo, papain increased ethmoid sinus mucosal thickening, serum IgE, PRG2/ALOX15 positive cells, and infiltration of CD45 immune cells, CD170 eosinophils, F4/80 macrophages, and B220 B cells. Baicalein significantly alleviated all these pathological changes. In conclusion, baicalein attenuates papain-induced eCRSwNP-like inflammation by inhibiting lipid peroxidation and ALOX15-associated M2 macrophage secretory function. The ALOX15/M2 macrophage axis may represent a potential therapeutic target for eCRSwNP. - Source: PubMed
Publication date: 2026/08/26
Wang LeiZhu ZhenzhenLiu YuzhuoAodeng SuritaKang TianhuiWang WeiqingLv Wei